vendredi 24 août 2018

Onco Actu du 24 août 2018

1. Biologie

Dana-Farber Lab Finds Misguided Gene Regulator at Fault in Prostate Cancer [Dana-Farber Cancer Institute]

2.10 Etiologie - Alcool

Early-life Alcohol Intake May Increase the Odds of High-grade Prostate Cancer Later in Life [AACR]

The risks of alcohol (again) [Medium]

No healthy level of alcohol consumption, says major study [The Guardian]

2.11 Etiologie - Alimentation

The Challenge of Reforming Nutritional Epidemiologic Research [JAMA]

2.6 Etiologie - Environnement

Bayer's Monsanto faces 8,000 lawsuits on glyphosate [Reuters]

3.1.1 Prévention - Tabac - e-cigs

Companies cease sales of e-liquids with labeling or advertising that resembled kid-friendly foods following FDA, FTC warnings [FDA]

3.3 Prévention - Vaccins

HPV-related cancer rates are rising. So are vaccine rates — just not fast enough. [Washingtom Post]

4. Dépistage, diagnostic et pronostic

How we label life experiences can lead to overdiagnosis [BMJ]

Big people, big data, and big problems [BMJ]

4.2 Dép., diag. & prono. - Génome

How scientists are trying to predict your future with your genes [Vox]

5.12.1 Immunothérapies - partenariats

Bluebird Bio Turns to Gritstone’s A.I. to Find TCR Cancer Targets [Xconomy]

bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies [bluebird bio]

Newly partnered with bluebird, Gritstone seeks $80M IPO in final dash for clinic [EndPoints]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Is It “Gene Therapy”? [Journal of Law and the Biosciences]

5.2 Pharma

Novartis’ PI3K drug hits goal in phase 3 breast cancer trial, laying groundwork for talks with regulators [FierceBiotech]

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation [Novartis]

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma [BMS]

5.2.1 Pharma - Partenariats

Pfizer, Astellas speed up 2 Xtandi studies in market duel with Johnson & Johnson [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

Need a placebo control group for your next cancer drug study? Only in certain circumstances, says FDA [EndPoints]

Hematologic Malignancy and Oncologic Disease: Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA® (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma [Merck]

5.4 Traitements - Economie

Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma [NICE]

6.1 Observation

AACR Project GENIE: More Data, More Participants, and More Progress [Cancer Research Catalyst]

Enhancements to NCI’s SEER Program Creating New Research Opportunities [NCI]

6.10 Politiques

UK calls for extra six weeks of Brexit drug stockpiles [Reuters]

6.7 DMP, Big Data & applis

23andMe will no longer let app developers read your DNA data [CNBC]